Other ROS1 inhibitors, including ceritinib and entrectinib (Figure 1), are currently under investigation in phase II clinical trials including patients with CCA and ROS1 and/or ALK genetic alterations, which occur in 1.1–8.7% of the cases [27] (Table 2). This evidence concerns the gene ROS1 and cholangiocarcinoma.